Pharmacokinetics of intravenous alendronateCOCQUYT, V; KLINE, W. F; PORRAS, A. G et al.Journal of clinical pharmacology. 1999, Vol 39, Num 4, pp 385-393, issn 0091-2700Article

Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in ratsOHNO, Yoshiyuki; YAMADA, Yasuhiko; USUI, Takashi et al.Biological & pharmaceutical bulletin. 2001, Vol 24, Num 11, pp 1290-1293, issn 0918-6158Article

Risques oculaires sous acide alendronique = Alendronic acid induced-ocular risksLa Revue Prescrire. 2001, Vol 21, Num 213, issn 0247-7750, p. 37Article

Bisphosphonate treatment of lytic bone metastasesLIPTON, A; BERENSON, J. R.Drugs & aging. 1999, Vol 14, Num 4, pp 241-246, issn 1170-229XArticle

Pharmacokinetics of clodronate in haemodialysis patientsALA-HOUHALA, I; SAHA, H; LIUKKO-SIPI, S et al.Nephrology, dialysis, transplantation (Print). 1999, Vol 14, Num 3, pp 699-705, issn 0931-0509Article

Bisphosphonates in the treatment of bone metastasesFINLEY, Rebecca S.Seminars in oncology. 2002, Vol 29, Num 1, pp 132-138, issn 0093-7754, SUP4Article

Use of bisphosphonates in skeletal metastasisELOMAA, Inkeri.Acta oncologica (Stockholm). 2000, Vol 39, Num 4, pp 445-454, issn 0284-186XArticle

Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cellsABE, Yasuyo; KAWAKAMI, Atsushi; ASHIZAWA, Kiyoto et al.The Journal of laboratory and clinical medicine. 2000, Vol 136, Num 5, pp 344-354, issn 0022-2143Article

Alendronate gastric ulcersGRAHAM, D. Y; MALATY, H. M.Alimentary pharmacology & therapeutics. 1999, Vol 13, Num 4, pp 515-519, issn 0269-2813Article

Factors influencing the role of bisphosphonates in breast cancer managementCHLEBOWSKI, Rowan T.Seminars in oncology. 2001, Vol 28, Num 4, pp 42-48, issn 0093-7754, SUP11Conference Paper

Bone metastases: approaches to managementJANJAN, Nora.Seminars in oncology. 2001, Vol 28, Num 4, pp 28-34, issn 0093-7754, SUP11Conference Paper

Bisphosphonates in the prevention of bone metastases: current evidenceDIEL, Ingo J.Seminars in oncology. 2001, Vol 28, Num 4, pp 75-80, issn 0093-7754, SUP11Conference Paper

Dosing regimens and main adverse events of bisphosphonatesBODY, Jean-Jacques.Seminars in oncology. 2001, Vol 28, Num 4, pp 49-53, issn 0093-7754, SUP11Conference Paper

Cellular and molecular mechanisms of action of bisphosphonatesROGERS, M. J; GORDON, S; BENFORD, H. L et al.Cancer. 2000, Vol 88, Num 12, pp 2961-2978, issn 0008-543X, SUPConference Paper

Traitement de l'ostéoporose chez l'homme : enfin une étude! = Male osteoporosis treatment efficacyDENDOUNE, Fadila.Concours médical (Paris). 2000, Vol 122, Num 34, issn 0010-5309, p. 2385Article

Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitroYLITALO, R; KALLIOVALKAMA, J; XIUMIN WU et al.Pharmacology & toxicology. 1998, Vol 83, Num 3, pp 125-131, issn 0901-9928Article

Monitoring esophageal transit of wax-polished Alendronate in healthy postmenopausal women: A new technique for the study of pill transit timeDRAKE, William M; WORSLEY, Daniel F; LENTLE, Brian C et al.Current therapeutic research. 2002, Vol 63, Num 2, pp 103-109, issn 0011-393XArticle

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancerPOWLES, Trevor; PATERSON, Sandy; PAJUNEN, Marjo et al.Journal of clinical oncology. 2002, Vol 20, Num 15, pp 3219-3224, issn 0732-183XArticle

Conventional treatment of hypercalcemia of malignancyDAVIDSON, Terri G.American journal of health-system pharmacy. 2001, Vol 58, pp S8-S15, issn 1079-2082, SUP3Article

Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysisSUDHOFF, Holger; JUNG, Jae Y; EBMEYER, Jörg et al.The Annals of otology, rhinology & laryngology. 2003, Vol 112, Num 9, pp 780-786, issn 0003-4894, 7 p., 1Article

Risedronate for the prevention and treatment of corticosteroid-induced osteoporosisDOUGHERTY, John A.The Annals of pharmacotherapy. 2002, Vol 36, Num 3, pp 512-516, issn 1060-0280Article

Advanced perspectives on and clinical usefulness of bisphosphonatesDAVIDSON, Terri G.American journal of health-system pharmacy. 2001, Vol 58, issn 1079-2082, 23 p., SUP3Serial Issue

Electrospray ionization mass spectrometry and tandem mass spectrometry of clodronate and related bisphosphonate and phosphonate compoundsHUIKKO, Katri; KOTIAHO, Tapio; YLI-KAUHALUOMA, Jari et al.Journal of mass spectrometry. 2002, Vol 37, Num 2, pp 197-208, issn 1076-5174Article

Risedronate for the prevention of fractures in postmenopausal osteoporosisSICKELS, Jennifer M; NIP, Chi-Sing.The Annals of pharmacotherapy. 2002, Vol 36, Num 4, pp 664-670, issn 1060-0280Article

A case study demonstrating superiority of a new compound over the gold standardQUEBE-FEHLING, Erhard.Drug information journal. 2001, Vol 35, Num 4, pp 1173-1178, issn 0092-8615Article